Do analysts rate CDXS or IBAC?

Codexis currently has a consensus price target of $6.50, indicating a potential upside of 345.21%. Given Codexis' stronger consensus rating and higher possible upside, equities analysts clearly believe Codexis is more favorable than IB Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Codexis 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 IB Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, CDXS or IBAC?

IB Acquisition has lower revenue, but higher earnings than Codexis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Codexis $70.39M 2.27 -$43.97M -$0.34 N/A IB Acquisition N/A N/A N/A N/A N/A

Does the media prefer CDXS or IBAC?

In the previous week, Codexis had 1 more articles in the media than IB Acquisition. MarketBeat recorded 2 mentions for Codexis and 1 mentions for IB Acquisition. Codexis' average media sentiment score of 1.74 beat IB Acquisition's score of -0.71 indicating that Codexis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Codexis 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive IB Acquisition 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Do analysts prefer QSI or IBAC?

Quantum-Si presently has a consensus target price of $1.00, suggesting a potential upside of 30.55%. Given Quantum-Si's stronger consensus rating and higher possible upside, equities research analysts clearly believe Quantum-Si is more favorable than IB Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quantum-Si 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 IB Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, QSI or IBAC?

IB Acquisition has lower revenue, but higher earnings than Quantum-Si. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Quantum-Si $2.44M 68.71 -$101.34M -$0.46 N/A IB Acquisition N/A N/A N/A N/A N/A

Do analysts recommend MXCT or IBAC?

MaxCyte currently has a consensus price target of $5.00, indicating a potential upside of 290.63%. Given MaxCyte's stronger consensus rating and higher possible upside, research analysts plainly believe MaxCyte is more favorable than IB Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MaxCyte 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 IB Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, MXCT or IBAC?

IB Acquisition has lower revenue, but higher earnings than MaxCyte. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MaxCyte $33.03M 4.00 -$44.63M -$0.33 N/A IB Acquisition N/A N/A N/A N/A N/A

Do analysts recommend IBAC or QTRX?

Quanterix has a consensus price target of $3.00, suggesting a potential upside of 11.52%. Given Quanterix's stronger consensus rating and higher possible upside, analysts plainly believe Quanterix is more favorable than IB Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IB Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Quanterix 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has higher earnings & valuation, IBAC or QTRX?

IB Acquisition has higher earnings, but lower revenue than Quanterix. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IB Acquisition N/A N/A N/A N/A N/A Quanterix $153.17M 0.83 -$107.15M -$2.63 N/A

Does the media prefer IBAC or QTRX?

In the previous week, IB Acquisition and IB Acquisition both had 1 articles in the media. Quanterix's average media sentiment score of 0.92 beat IB Acquisition's score of -0.71 indicating that Quanterix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IB Acquisition 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Quanterix 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend IBAC or NAUT?

Nautilus Biotechnology has a consensus price target of $4.00, indicating a potential upside of 342.04%. Given Nautilus Biotechnology's stronger consensus rating and higher possible upside, analysts plainly believe Nautilus Biotechnology is more favorable than IB Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IB Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Nautilus Biotechnology 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings and valuation, IBAC or NAUT?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IB Acquisition N/A N/A N/A N/A N/A Nautilus Biotechnology N/A N/A -$59M -$0.45 N/A

Is IBAC or NAUT more profitable?

IB Acquisition's return on equity of 0.00% beat Nautilus Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets IB Acquisition N/A N/A N/A Nautilus Biotechnology N/A -37.58% -30.83%

Does the media prefer IBAC or NAUT?

In the previous week, Nautilus Biotechnology had 1 more articles in the media than IB Acquisition. MarketBeat recorded 2 mentions for Nautilus Biotechnology and 1 mentions for IB Acquisition. Nautilus Biotechnology's average media sentiment score of 0.00 beat IB Acquisition's score of -0.71 indicating that Nautilus Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IB Acquisition 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Nautilus Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

IB Acquisition (IBAC) Competitors

$10.89 0.00 (0.00%)

As of 09/4/2026 03:55 PM Eastern

Compare

IBAC vs. CDXS, QSI, MXCT, QTRX, and NAUT

Should you buy IB Acquisition stock or one of its competitors? IB Acquisition's main competitors and comparable companies include Codexis (CDXS), Quantum-Si (QSI), MaxCyte (MXCT), Quanterix (QTRX), and Nautilus Biotechnology (NAUT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does IB Acquisition compare to Codexis?

Codexis (NASDAQ:CDXS) and IB Acquisition (NASDAQ:IBAC) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment and analyst recommendations.

In the previous week, Codexis had 1 more articles in the media than IB Acquisition. MarketBeat recorded 2 mentions for Codexis and 1 mentions for IB Acquisition. Codexis' average media sentiment score of 1.74 beat IB Acquisition's score of -0.71 indicating that Codexis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Codexis	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
IB Acquisition	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

IB Acquisition has a net margin of 0.00% compared to Codexis' net margin of -39.55%. IB Acquisition's return on equity of 0.00% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Codexis	-39.55%	-74.36%	-23.58%
IB Acquisition	N/A	N/A	N/A

Codexis currently has a consensus price target of $6.50, indicating a potential upside of 345.21%. Given Codexis' stronger consensus rating and higher possible upside, equities analysts clearly believe Codexis is more favorable than IB Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Codexis	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
IB Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

78.5% of Codexis shares are owned by institutional investors. 3.5% of Codexis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

IB Acquisition has lower revenue, but higher earnings than Codexis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Codexis	$70.39M	2.27	-$43.97M	-$0.34	N/A
IB Acquisition	N/A	N/A	N/A	N/A	N/A

Summary

Codexis beats IB Acquisition on 8 of the 11 factors compared between the two stocks.

How does IB Acquisition compare to Quantum-Si?

Quantum-Si (NASDAQ:QSI) and IB Acquisition (NASDAQ:IBAC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

39.9% of Quantum-Si shares are held by institutional investors. 22.0% of Quantum-Si shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

IB Acquisition has a net margin of 0.00% compared to Quantum-Si's net margin of -6,138.26%. IB Acquisition's return on equity of 0.00% beat Quantum-Si's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quantum-Si	-6,138.26%	-47.12%	-43.18%
IB Acquisition	N/A	N/A	N/A

Quantum-Si presently has a consensus target price of $1.00, suggesting a potential upside of 30.55%. Given Quantum-Si's stronger consensus rating and higher possible upside, equities research analysts clearly believe Quantum-Si is more favorable than IB Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quantum-Si	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
IB Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, IB Acquisition had 1 more articles in the media than Quantum-Si. MarketBeat recorded 1 mentions for IB Acquisition and 0 mentions for Quantum-Si. Quantum-Si's average media sentiment score of 0.00 beat IB Acquisition's score of -0.71 indicating that Quantum-Si is being referred to more favorably in the media.

Company	Overall Sentiment
Quantum-Si	Neutral
IB Acquisition	Negative

IB Acquisition has lower revenue, but higher earnings than Quantum-Si.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quantum-Si	$2.44M	68.71	-$101.34M	-$0.46	N/A
IB Acquisition	N/A	N/A	N/A	N/A	N/A

Summary

Quantum-Si beats IB Acquisition on 7 of the 11 factors compared between the two stocks.

How does IB Acquisition compare to MaxCyte?

MaxCyte (NASDAQ:MXCT) and IB Acquisition (NASDAQ:IBAC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, media sentiment, valuation, risk, analyst recommendations and institutional ownership.

68.8% of MaxCyte shares are held by institutional investors. 4.1% of MaxCyte shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

MaxCyte currently has a consensus price target of $5.00, indicating a potential upside of 290.63%. Given MaxCyte's stronger consensus rating and higher possible upside, research analysts plainly believe MaxCyte is more favorable than IB Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MaxCyte	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
IB Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

IB Acquisition has a net margin of 0.00% compared to MaxCyte's net margin of -114.77%. IB Acquisition's return on equity of 0.00% beat MaxCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MaxCyte	-114.77%	-18.92%	-16.14%
IB Acquisition	N/A	N/A	N/A

IB Acquisition has lower revenue, but higher earnings than MaxCyte.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MaxCyte	$33.03M	4.00	-$44.63M	-$0.33	N/A
IB Acquisition	N/A	N/A	N/A	N/A	N/A

In the previous week, IB Acquisition had 1 more articles in the media than MaxCyte. MarketBeat recorded 1 mentions for IB Acquisition and 0 mentions for MaxCyte. MaxCyte's average media sentiment score of 0.00 beat IB Acquisition's score of -0.71 indicating that MaxCyte is being referred to more favorably in the media.

Company	Overall Sentiment
MaxCyte	Neutral
IB Acquisition	Negative

Summary

MaxCyte beats IB Acquisition on 7 of the 11 factors compared between the two stocks.

How does IB Acquisition compare to Quanterix?

IB Acquisition (NASDAQ:IBAC) and Quanterix (NASDAQ:QTRX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership.

86.5% of Quanterix shares are owned by institutional investors. 1.5% of Quanterix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

IB Acquisition has higher earnings, but lower revenue than Quanterix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IB Acquisition	N/A	N/A	N/A	N/A	N/A
Quanterix	$153.17M	0.83	-$107.15M	-$2.63	N/A

IB Acquisition has a net margin of 0.00% compared to Quanterix's net margin of -80.25%. IB Acquisition's return on equity of 0.00% beat Quanterix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IB Acquisition	N/A	N/A	N/A
Quanterix	-80.25%	-26.09%	-19.03%

In the previous week, IB Acquisition and IB Acquisition both had 1 articles in the media. Quanterix's average media sentiment score of 0.92 beat IB Acquisition's score of -0.71 indicating that Quanterix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IB Acquisition	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
Quanterix	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Quanterix has a consensus price target of $3.00, suggesting a potential upside of 11.52%. Given Quanterix's stronger consensus rating and higher possible upside, analysts plainly believe Quanterix is more favorable than IB Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IB Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Quanterix	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Quanterix beats IB Acquisition on 6 of the 9 factors compared between the two stocks.

How does IB Acquisition compare to Nautilus Biotechnology?

IB Acquisition (NASDAQ:IBAC) and Nautilus Biotechnology (NASDAQ:NAUT) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk and profitability.

50.7% of Nautilus Biotechnology shares are owned by institutional investors. 41.1% of Nautilus Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

IB Acquisition's return on equity of 0.00% beat Nautilus Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IB Acquisition	N/A	N/A	N/A
Nautilus Biotechnology	N/A	-37.58%	-30.83%

In the previous week, Nautilus Biotechnology had 1 more articles in the media than IB Acquisition. MarketBeat recorded 2 mentions for Nautilus Biotechnology and 1 mentions for IB Acquisition. Nautilus Biotechnology's average media sentiment score of 0.00 beat IB Acquisition's score of -0.71 indicating that Nautilus Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IB Acquisition	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
Nautilus Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IB Acquisition	N/A	N/A	N/A	N/A	N/A
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.45	N/A

Nautilus Biotechnology has a consensus price target of $4.00, indicating a potential upside of 342.04%. Given Nautilus Biotechnology's stronger consensus rating and higher possible upside, analysts plainly believe Nautilus Biotechnology is more favorable than IB Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IB Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Nautilus Biotechnology beats IB Acquisition on 7 of the 9 factors compared between the two stocks.

Get IB Acquisition News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IBAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IBAC vs. The Competition

Export

Metric	IB Acquisition	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$54.54M	$10.03B	$7.27B	$12.92B
Dividend Yield	N/A	1.46%	2.54%	8.90%
P/E Ratio	N/A	65.01	272.43	25.42
Price / Sales	N/A	112.04	637.14	97.20
Price / Cash	N/A	27.04	77.39	52.28
Price / Book	N/A	35.98	12.85	6.17
Net Income	N/A	$56.67B	$3.47B	$349.50M
7 Day Performance	N/A	-0.79%	0.97%	-0.15%
1 Month Performance	0.65%	4.00%	5.47%	1.02%
1 Year Performance	3.13%	26.50%	24.29%	14.50%

IB Acquisition Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IBAC IB Acquisition	N/A	$10.89 flat	N/A	+3.2%	$54.54M	N/A	N/A	N/A	News Coverage High Trading Volume
CDXS Codexis	4.0856 of 5 stars	$1.59 -4.2%	$6.50 +308.8%	-39.7%	$174.12M	$70.39M	N/A	250	Positive News Analyst Downgrade
QSI Quantum-Si	2.5696 of 5 stars	$0.78 -2.9%	$1.00 +28.2%	-28.4%	$170.73M	$2.44M	N/A	150
MXCT MaxCyte	2.5573 of 5 stars	$1.22 -4.7%	$5.00 +309.8%	-5.9%	$125.91M	$31.05M	N/A	80
QTRX Quanterix	1.3846 of 5 stars	$2.64 flat	$3.00 +13.6%	-37.7%	$124.85M	$138.90M	N/A	460

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IBAC) was last updated on 9/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IB Acquisition (IBAC) Competitors

IBAC vs. CDXS, QSI, MXCT, QTRX, and NAUT

How does IB Acquisition compare to Codexis?

Summary

How does IB Acquisition compare to Quantum-Si?

Summary

How does IB Acquisition compare to MaxCyte?

Summary

How does IB Acquisition compare to Quanterix?

Summary

How does IB Acquisition compare to Nautilus Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBAC vs. The Competition

IB Acquisition Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

IB Acquisition (IBAC) Competitors

IBAC vs. CDXS, QSI, MXCT, QTRX, and NAUT

How does IB Acquisition compare to Codexis?

Does the media prefer CDXS or IBAC?

Is CDXS or IBAC more profitable?

Do analysts rate CDXS or IBAC?

Do insiders and institutionals have more ownership in CDXS or IBAC?

Which has preferable valuation and earnings, CDXS or IBAC?

Summary

How does IB Acquisition compare to Quantum-Si?

Do insiders and institutionals hold more shares of QSI or IBAC?

Is QSI or IBAC more profitable?

Do analysts prefer QSI or IBAC?

Does the media prefer QSI or IBAC?

Which has better earnings and valuation, QSI or IBAC?

Summary

How does IB Acquisition compare to MaxCyte?

Do institutionals & insiders believe in MXCT or IBAC?

Do analysts recommend MXCT or IBAC?

Is MXCT or IBAC more profitable?

Which has better valuation & earnings, MXCT or IBAC?

Does the media refer more to MXCT or IBAC?

Summary

How does IB Acquisition compare to Quanterix?

Do insiders and institutionals hold more shares of IBAC or QTRX?

Which has higher earnings & valuation, IBAC or QTRX?

Is IBAC or QTRX more profitable?

Does the media prefer IBAC or QTRX?

Do analysts recommend IBAC or QTRX?

Summary

How does IB Acquisition compare to Nautilus Biotechnology?

Do institutionals & insiders believe in IBAC or NAUT?

Is IBAC or NAUT more profitable?

Does the media prefer IBAC or NAUT?

Which has higher earnings and valuation, IBAC or NAUT?

Do analysts recommend IBAC or NAUT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBAC vs. The Competition

IB Acquisition Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools